`
`
`
`IN THE UNITED STATES DISTRICT COURT
`FOR THE DISTRICT OF DELAWARE
`
`
`MEDA PHARMACEUTICALS INC. and
`CIPLA LTD.,
`
`)
`)
`)
`)
`)
`C.A. No. 14-1453-LPS
`)
`
`)
`)
`)
`)
`
`
`
`
`
`
`
`Plaintiffs,
`
`v.
`
`
`
`
`
`
`APOTEX INC. and APOTEX CORP.,
`
`
`
`
`
`Defendants.
`
`
`
`JOINT CLAIM CONSTRUCTION CHART
`
`Pursuant to paragraph 11 of the Scheduling Order (D.I. 18), entered by the Court on April
`
`14, 2015, the parties jointly submit their Joint Claim Construction Chart which provides the
`
`parties’ respective proposed constructions of the disputed claim terms with citations to the
`
`intrinsic evidence in support of their construction as Exhibit A. The parties agree no other terms
`
`in the asserted claims require construction at this time. In Exhibits 1-82, the parties submit the
`
`sections of the intrinsic record upon which they intend to rely.
`
`In order to simplify the issues for the Court, the parties have agreed not to present expert
`
`discovery in the briefs, at the Markman hearing, or in their respective technology tutorials. The
`
`parties reserve the right to alter their constructions based on further discovery and their
`
`continuing analysis. Each party's citations shall not be construed so as to prohibit the parties
`
`from addressing the opposing party's designations.
`
`
`
`
`
`
`
`{01056049;v1 }
`
`
`
`
`Case 1:14-cv-01453-LPS Document 43 Filed 10/22/15 Page 2 of 16 PageID #: 205
`
`
`
`
`
`
`
`POTTER ANDERSON & CORROON, LLP
`
`/s/ Bindu A. Palapura
`
`
`
`
`Richard L. Horwitz (#2246)
`David E. Moore (#3983)
`Bindu A. Palapura (#5370)
`1313 North Market Street
`Hercules Plaza, 6th Floor
`Wilmington, DE 19801
`(302) 984-6000
`rhorwitz@potteranderson.com
`dmoore@potteranderson.com
`bpalapura@potteranderson.com
`
`Attorneys for Defendants Apotex Inc.
`and Apotex Corp.
`
`Of Counsel:
`
`Tung-On Kong, Esq.
`WILSON SONSINI GOODRICH &
`ROSATI
`One Market Plaza
`Spear Tower, Suite 3300
`San Francisco, CA 94105
`(415) 947-2000
`
`Nicole W. Stafford, Esq.
`Robert A. Delafield, II, Esq.
`WILSON SONSINI GOODRICH &
`ROSATI
`900 South Capital of Texas Highway
`Las Cimas IV, Fifth Floor
`Austin, TX 78746
`(512) 338-5400
`
`
`
`
`
`
`ASHBY & GEDDES
`
`/s/ Andrew C. Mayo
`
`
`Steven J. Balick (#2114)
`John G. Day (#2403)
`Andrew C. Mayo (#5207)
`500 Delaware Ave., 8th Floor
`P.O. Box 1150
`Wilmington, DE 19899
`(302) 654-1888
`sbalick@ashby-geddes.com
`jday@ashby-geddes.com
`amayo@ashby-geddes.com
`
`Attorneys for Plaintiffs Meda
`Pharmaceuticals Inc. and Cipla Ltd.
`
`Of Counsel:
`
`H. Keeto Sabharwal
`Uma N. Everett
`Dennies Varughese
`Rami Bardenstein
`Dallin G. Glenn
`Diane E. Ghrist
`Josephine J. Kim, Esq.
`STERNE, KESSLER, GOLDSTEIN & FOX
`PLLC
`1100 New York Ave., N.W., Suite 800
`Washington, DC 20005-3934
`(202) 371-2600
`
`
`
`Dated: October 22, 2015
`
`{01056049;v1 }
`
`- 2 -
`
`
`
`Case 1:14-cv-01453-LPS Document 43 Filed 10/22/15 Page 3 of 16 PageID #: 206
`
`
`
`
`
`
`
`
`
`
`
`
`
`EXHIBIT A
`
`{01056049;v1 }
`
`
`
`
`
`
`
`
`
`
`Case 1:14-cv-01453-LPS Document 43 Filed 10/22/15 Page 4 of 16 PageID #: 207
`
`Exhibit A
`Disputed Terms and Proposed Constructions1
`
`
`Term
`
`Term/Phrase
`
`Asserted Patent
`Claim(s)
`
`Plaintiffs’ Proposed Construction
`and Intrinsic Evidence
`
`Defendants’ Proposed Construction
`and Intrinsic Evidence
`
`1
`
`“condition(s)”
`
`’723 patent: 1-4, 7, 8,
`10-18, 20-28
`
`’620 patent: 16, 17,
`24
`
`Proposed Construction
`
`Proposed Construction
`
`“condition(s) resulting in or causing
`allergic reaction(s)”
`
`Intrinsic Evidence
`
`’723 patent
`(MED_DYM_00018010-
`MED_DYM_00018025): abstract,
`1:19-62; 1:66-2:5; 2:16-31; 3:27-32;
`3:38-41; 4:7-32; 4:41-53; 4:61-5:4;
`5:47-6:2; 6:10-28; 7:1-27; 7:53-64;
`8:5-11:47 (Examples 1-14); claims
`1, 4-9, 17, 25.
`
`’723 patent PH:
`
`MED_DYM_11300-
`MED_DYM_00011301 (November
`23, 2011 Examiner-Initiated
`
`Plain and ordinary meaning.
`
`To the extent the Court determines that
`this term requires construction, Apotex
`proposes the following construction:
`“disease(s) or illness(es).”
`
`Intrinsic Evidence
`
`’723 patent: Col. 1:35-62; 2:15-26;
`4:41-54; 5:46-58; 6:46-54; 7:19-64;
`claims 1-4, 7, 8, 10-18, 20-28;
`MED_DYM_00018010-18025
`
`’620 patent: Col. 1:26-33; 2:15-27;
`4:41-54; 5:47-59; 6:46-54; 7:19-64;
`claims 16, 17, 24;
`MED_DYM_00018026-18041
`
`
`1 For all citations, the parties incorporate the corresponding passages in the other patent that are substantially duplicative of the
`specification, figures and abstract citations cited.
`
`{01056049;v1 }
`
`- 1 -
`
`
`
`
`
`Case 1:14-cv-01453-LPS Document 43 Filed 10/22/15 Page 5 of 16 PageID #: 208
`
`Interview Summary).
`
`MED_DYM_00014516-
`MED_DYM_00014525 (December
`12, 2011 Preliminary Amendment).
`
`MED_DYM_00017819-
`MED_DYM_00017826 (January 26,
`2012 Notice of Allowance), see
`specifically MED_DYM_00017823,
`MED_DYM_00017825.
`
`’620 patent
`(MED_DYM_00018026-
`MED_DYM_00018041): abstract,
`1:10-60; 2:15-30; 3:25-30; 3:36-39;
`4:7-32; 4:41-53; 4:61-5:4; 5:48-6:3;
`6:11-28; 7:1-27; 7:53-64; 8:4-11:43
`(Examples 1-11 and unnumbered
`Examples); claims 1, 7, 9, 13-17, 19,
`24, 25, 28-30, 47-48.
`
`’620 patent PH:
`
`MED_DYM_00000002-
`MED_DYM_00000043 (Transmittal
`of New Application and
`PCT/GB03/02557).
`
`MED_DYM_00000254-
`MED_00000275 (January 23, 2009
`Office Action), see specifically
`MED_DYM_00000266,
`
`U.S. Patent App. Pub. 2009/0291143,
`pp. 1-4, APOTEX_AZFL 0053674-
`53681
`
`U.S. Patent App. Pub. 2009/0318397,
`pp. 1-4, APOTEX_AZFL 0053682-
`689
`
`U.S. Patent No. 2,837,464, Col. 2, 5;
`APOTEX_AZFL 0053838-848
`
`U.S. Patent No. 3,067,197 Col. 10;
`APOTEX_AZFL 0053849-859
`
`U.S. Patent Application No.
`12/879,515, August 16, 2011
`Declaration of Dr. Sujeet Rajan, pp. 1-
`5; APOTEX_AZFL 0061477-481
`
`U.S. Patent Application No.
`10/518,016 filed as PCT No.
`PCT/GB03/02557 (WO 03/105856)
`Original Application, pp. 1, 5-10, 19-
`23; MED_DYM_0000020-000043
`
`PCT application EP02/02317 (WO
`02/070490 AI) (published 9/12/02)
`pp.1-97,
`MED_DYM_00000143 to 240 at 155
`
`July 23, 2009 Response to Office
`Action, pp. 11-18;
`MED_DYM_0000288-306
`
`{01056049;v1 }
`
`- 2 -
`
`
`
`
`
`Case 1:14-cv-01453-LPS Document 43 Filed 10/22/15 Page 6 of 16 PageID #: 209
`
`MED_DYM_00000270.
`
`MED_DYM_00000288-
`MED_DYM_00000306 (July 23,
`2009 Amendments and Response To
`Office Action Dated January 23,
`2009), see specifically
`MED_DYM_00000302-
`MED_DYM_00000304.
`
`MED_DYM_00000577-
`MED_DYM_00000596 (April 28,
`2010 Office Action), see specifically
`MED_DYM_00000582,
`MED_DYM_00000594.
`
`MED_DYM_00000609-
`MED_DYM_00000629 (September
`24, 2010 Amendments and
`Response to Final Office Action
`Dated April 28, 2010), see
`specifically MED_DYM_00000613-
`MED_DYM_000000617,
`MED_DYM_00000622,
`MED_DYM_00000627-
`MED_DYM_00000628.
`
`MED_DYM_00000765-
`MED_DYM_00000780 (February
`16, 2011 Office Action), see
`specifically MED_DYM_00000769,
`MED_DYM_00000773,
`MED_DYM_00000775-
`
`April 28, 2010 Office Action, pp. 1-
`17, MED_DYM_0000578-594
`
`September 24, 2010 Response to
`Office Action, pp. 1-15,
`MED_DYM_0000609-623
`
`August 16, 2011 Amendments and
`Response to Office Action, pp. 1-29,
`MED_DYM_0000793-820
`
`Busse W W et al: “Corticosteroid-
`Sparing Effect of Azelastine in the
`Management of Bronchial Asthma”—
`American Journal of Respiratory and
`Critical Care Medicine, American
`Lung Association, new York, NW,
`vol. 153, No. 1, 1996, pp. 122-127.
`MED_DYM_00000128-133.
`
`Database Medline Online! US
`National Library of Medicine (NLM),
`Bethesda, MD, US: 2000 Portmann D
`et al: Acceptability of local treatment
`of allergic rhinitis with a combination
`of a corticoid (beclomethasone) and an
`antihistaminic (azelastine); vol. 121,
`No. 4, 2000, pp. 273-279, Abstract.
`MED_DYM_0000135
`
`Foreign communication Examination
`Report, EP Application 03738280.1,
`Nov. 10, 2005, pp.1-4, MED-
`
`{01056049;v1 }
`
`- 3 -
`
`
`
`
`
`Case 1:14-cv-01453-LPS Document 43 Filed 10/22/15 Page 7 of 16 PageID #: 210
`
`MED_DYM_00000777.
`
`DYM0000431-434
`
`MED_DYM_00000793-
`MED_DYM_00000820 (August 16,
`2011 Amendments and Response to
`Office Action Dated February 16,
`2011), see specifically
`MED_DYM_00000794,
`MED_DYM_00000798-
`MED_DYM_00000801,
`MED_DYM_00000806,
`MED_DYM_00000815-
`MED_DYM_00000818.
`
`MED_DYM_00002559-
`MED_DYM_00002571 (October 3,
`2011 Notice of Allowance), see
`specifically MED_DYM_00002567-
`MED_DYM_00002568-
`MED_DYM_00002570.
`
`MED_DYM_00009006-
`MED_DYM_00009014 (January 30,
`2012 Supplemental Notice of
`Allowability).
`
`MED_DYM_00001454-
`MED_DYM_00001460 (Chopra
`Declaration Submitted with August
`16, 2011 Amendment), see
`specifically MED_DYM_00001454-
`MED_DYM_00001460.
`
`MED_DYM_00001334-
`
`Foreign communication from the
`priority application—International
`Preliminary Examination Report,
`PCT/GB03/02557, Aug. 26, 2004, pp.
`1-4, MED-DYM_00000435-440.
`
`Dykewicz, Mark S., et al., “Diagnosis
`and management of rhinitis: complete
`guidelines of the joint task force on
`practice parameters in allergy, asthma
`and immunology,” Annals of Allergy,
`Asthma & Immunology, Nov. (Part II)
`1998, vol. 81, pp. 478-518,
`MED_DYM_00000504-544.
`
`Schmidt, M. W., “The new topical
`steroid ciclesonide is effective in the
`treatment of allergic rhinitis,” Journal
`of Clinical Pharmacology, 1999, vol.
`39, pp. 1062-1069,
`MED_DYM_00000726-733.
`
`First Official Action Translation,
`MED_DYM_00002016-021 at 019
`
`Galant, S., et al., “Clinical Prescribing
`of Allergic Rhinitis Medication in the
`Preschool and Young School-Age
`Child, What are the Options?,”
`BioDrugs2001, vol. 15, No. 7, pp.
`453-463, ADIS International Ltd.
`
`{01056049;v1 }
`
`- 4 -
`
`
`
`
`
`Case 1:14-cv-01453-LPS Document 43 Filed 10/22/15 Page 8 of 16 PageID #: 211
`
`MED_DYM_00001433 (Maus
`Declaration), see specifically
`MED_DYM_00001335-
`MED_DYM_00001340,
`MED_DYM_00001347,
`MED_DYM_00001357,
`MED_DYM_00001368,
`MED_DYM_00001374,
`MED_DYM_00001383,
`MED_DYM_00001403.
`
`MED_DYM_00001434-
`MED_DYM_00001453 (Rajan
`Declaration), see specifically
`MED_DYM_00001435-
`MED_DYM_00001437.
`
`Plaintiffs reserve the right to rely
`upon any intrinsic evidence cited by
`Defendants.
`
`MED_DYM_00002148-158 at 149
`
`Baena-Cagnani, C., “Safety and
`Tolerability of Treatments for Allergic
`Rhinitis in Children,” Drug Safety
`2004, vol. 27, No. 12, pp. 883-898,
`ADIS Data Information BV
`MED_DYM_00002199-214 at 210
`
`Gawchik, et al., “Comparison of
`intranasal triamcinolone acetonide
`with oral loratadine in the treatment of
`seasonal ragweed-induced allergic
`rhinitis,” Am. J. Man. Care, 1997, vol.
`3, No. 7, pp. 1052-1058.
`MED_DYM_00002724-730 at 724
`
`PCT application PCT/GB02i04602
`(WO/2003/033000) (Published
`4/24/03) pp. 1-14
`MED_DYM_00003848-866 at 849-
`850
`
`WO/1997/024365, pp. 6-7,
`MED_DYM_00004062-4082
`
`WO/2003/066656, pp. 9-10,
`MED_DYM_00004210-4220
`
`WO/1997/021724, pp. 1, 2, 5,
`MED_DYM_00004328-4332
`
`WO/2004/013156, pp. 3-6,
`
`{01056049;v1 }
`
`- 5 -
`
`
`
`
`
`Case 1:14-cv-01453-LPS Document 43 Filed 10/22/15 Page 9 of 16 PageID #: 212
`
`MED_DYM_00004369-4376
`
`WO/2003/013427, pp. 1-2
`MED_DYM_00004390-4391
`
`WO/2002/076933, pp. 7-8,
`MED_DYM_00004417-4425
`
`WO/1999/025359, pp. 7, 10
`MED_DYM_00004584-4594
`
`WO/2003/042229, pp. 5,
`MED_DYM_00004612-4617
`
`WO/2003/066033, pp. 1, 14,
`MED_DYM_00004671-4685
`
`WO/2008/012338, pp. 1, 14,
`MED_DYM_00004849-4863
`
`Nielsen, et al., “Intranasal
`corticosteroids for allergic rhinitis:
`superior relief?” Drugs, 2001, vol. 61,
`No. 11, pp. 1563-1573,
`MED_DYM_00005344-5354.
`
`Salib Rami Jean, et al., “Safety and
`Tolerability Profiles of Intranasal
`Antihistamines and Intranasal
`Corticosteroids in the Treatment of
`Allergic Rhinitis,” Drug Safety 2003,
`vol. 26, No. 12, pp. 863-893, ADIS
`Data Information BV,
`MED_DYM_00005869-5892
`
`{01056049;v1 }
`
`- 6 -
`
`
`
`
`
`Case 1:14-cv-01453-LPS Document 43 Filed 10/22/15 Page 10 of 16 PageID #: 213
`
`WO/2000/066522, pp. 96,
`MED_DYM_00006001-6008
`Case 1:14—cv—O1453—LPS Document 43 Filed 10/22/15 Page 10 of 16 Page|D #: 213
`WO/2002/012266, pp. 7-8,
`MED_DYM_00006198-6206
`
`EP0416951, pp. 2,
`MED_DYM_00006263-6264
`WO/2000/066522, pp. 96,
`MED_DYM_00006001-6008
`WO/2001/078736, pp. 3-4, 12,
`MED_DYM_00006587-6599
`W0/2002/012266, pp. 7-8,
`MED_DYM_00006198-6206
`WO/2000/016814, pp. 1, 9,
`MED_DYM_00006604-6614
`EP0416951, pp. 2,
`MED_DYM_00006263-6264
`GB2140800, pp. 3,
`MED_DYM_00006621-6624
`W0/2001/078736, pp. 3-4, 12,
`MED_DYM_00006587-6599
`WO/2000/048587, pp. 1-7,
`MED_DYM_00007157-7165
`W0/2000/016814, pp. 1, 9,
`MED_DYM_00006604-6614
`WO/2001/078741, pp. 1-7,
`MED_DYM_00007775-7782
`GB2140800, pp. 3,
`MED_DYM_00006621-6624
`WO/2001/078739, pp. 1-7,
`MED_DYM_00007791-
`W0/2000/048587, pp. 1-7,
`7802WO/2001/078745, pp. 3, 13,
`MED_DYM_00007157-7165
`MED_DYM_00008003-8016
`W0/2001/078741, pp. 1-7,
`WO/2001/054664, pp. 1,
`MED_DYM_00007775-7782
`MED_DYM_00008143-8144
`W0/2001/078739, pp. 1-7,
`WO/2000/033892, pp. 1,
`MED_DYM_00007791-
`MED_DYM_00008280-8281
`7802WO/2001/078745, pp. 3, 13,
`MED_DYM_00008003-8016
`
`{01056049;v1 }
`
`- 7 -
`
`W0/2001/054664, pp. 1,
`MED_DYM_00008143-8144
`
`W0/2000/033892, pp. 1,
`MED_DYM_00008280-8281
`
`
`
`
`
`Case 1:14-cv-01453-LPS Document 43 Filed 10/22/15 Page 11 of 16 PageID #: 214
`
`WO/2002/066422, pp. 7-9,
`MED_DYM_00008571-8580
`
`WO/2002/100879, pp. 1, 5,
`MED_DYM_00008683-8688
`
`WO/2002/026723, pp. 23-24,
`MED_DYM_00008775-8798
`
`U.S. Patent Application No.
`12/879,515, Original Application, pp.
`1-2, 8, 10-13; MED_DYM_00009277-
`9302
`
`August 16, 2011 Declaration of Dr.
`Joachim Maus, pp. 1-7;
`MED_DYM_00009966-9971
`
`U.S. Patent Application Publication
`No. U.S. 2004/0235807 A1 (published
`11/25/04) MED_DYM_00011174-191
`at 179.
`
`WO/1999/001467, pp.33,
`MED_DYM_00011939-1973
`
`WO/1999/025359, pp. 7,
`MED_DYM_00012676-2684
`
`Defendants reserve the right to rely
`upon any intrinsic evidence cited by
`Plaintiffs
`
`{01056049;v1 }
`
`- 8 -
`
`
`
`
`
`Case 1:14-cv-01453-LPS Document 43 Filed 10/22/15 Page 12 of 16 PageID #: 215
`
`2
`
`“administration”
`
`’723 patent: 1-4, 7, 8,
`10-18, 20-28
`
`’620 patent: 1-13, 15-
`18, 21, 22, 24-26, 28,
`29, 31, 33, 35-47
`
`Proposed Construction
`
`Proposed Construction
`
`Plain and ordinary meaning. To the
`extent that the Court requires further
`explanation of the plain and ordinary
`meaning of “administration,”
`Plaintiffs propose that the plain and
`ordinary meaning of
`“administration” is “application.”
`
`Intrinsic Evidence
`
`’723 patent
`(MED_DYM_00018010-
`MED_DYM_00018025): title,
`abstract, 1:43-62; 1:66-2:5; 2:19-3:7;
`3:38-41; 3:54-4:32; 4:41-5:4; 5:14-
`20; 5:30-7:64; 8:4-11:48 (Examples
`1-14); claims 1, 4-6, 12-21, 24-28.
`
`’723 patent PH:
`
`MED_DYM_11300-
`MED_DYM_00011301 (November
`23, 2011 Examiner-Initiated
`Interview Summary).
`
`MED_DYM_00014516-
`MED_DYM_00014525 (December
`12, 2011 Preliminary Amendment).
`
`MED_DYM_00017819-
`MED_DYM_00017826 (January 26,
`
`“to administer simultaneously, either
`in the same or different
`pharmaceutical formulations, or
`separately or sequentially”
`
`Intrinsic Evidence
`
`’723 patent: Col. 1:43-63; 4:41-53, 61-
`67; 5:1-4, 47-67; 6:1-2, 46-54; 7:18-
`27, 35-52; claims 1-4, 7, 8, 10-18, 20-
`28; MED_DYM_00018010-18025
`
`’620 patent: Col. 1:39-53; 4:41-53, 61-
`67; 5:1-4, 48-67; 6:1-3, 46-55; 7:18-
`27, 35-52; claims 1-13, 15-18, 21, 22,
`24-26, 28, 29, 31, 33, 35-47;
`MED_DYM_00018026-18041
`
`U.S. Patent App. Pub. 2009/0318397,
`pp. 1-4, APOTEX_AZFL 0053682-
`689
`
`U.S. Patent App. Pub. 2009/0291143,
`pp. 1-4, APOTEX_AZFL 0053674-
`681
`
`U.S. Patent Application No.
`10/518,016 filed as PCT No.
`PCT/GB03/02557 (WO 03/105856),
`Original Application, pp. 1-2, 5-10,
`19-23, MED_DYM_0000020-43Great
`
`{01056049;v1 }
`
`- 9 -
`
`
`
`
`
`Case 1:14-cv-01453-LPS Document 43 Filed 10/22/15 Page 13 of 16 PageID #: 216
`
`2012 Notice of Allowance), see
`specifically MED_DYM_00017823,
`MED_DYM_00017825.
`
`’620 patent
`(MED_DYM_00018026-
`MED_DYM_00018041): title,
`abstract, 1:34-2:6; 2:14-3:6; 3:36-39;
`3:52-4:32; 4:41-5:4; 5:13-19; 5:31-
`7:64; 8:4-11:44 (Examples 1-11 and
`unnumbered Examples); claims 1, 5-
`21, 24-34, 38-44, 47-48.
`
`’620 patent PH:
`
`MED_DYM_00000002-
`MED_DYM_00000043 (Transmittal
`of New Application and
`PCT/GB03/02557), see specifically
`MED_DYM_00000039-
`MED_DYM_00000043.
`
`MED_DYM_00000064-
`MED_DYM_00000076 (December
`14, 2004 Preliminary Amendment),
`see specifically
`MED_DYM_00000070-
`MED_DYM_00000076.
`
`MED_DYM_00000254-
`MED_00000275 (January 23, 2009
`Office Action), see specifically
`MED_DYM_00000255,
`
`Britain Appln. No. 0213739.6, pp. 1-
`10, MED_DYM0000082-93
`
`July 23, 2009 Response to Office
`Action, pp. 11-18;
`MED_DYM_0000288-306
`
`April 28, 2010 Office Action, pp. 1-
`17, MED_DYM_0000578-594
`
`September 24, 2010 Response to
`Office Action, pp. 1-15,
`MED_DYM_0000609-623
`
`August 16, 2011 Amendments and
`Response to Office Action, pp. 1-29,
`MED_DYM_0000793-820
`
`EP 1 519 731 B1, pp. 1-11,
`MED_DYM_00000348-358
`
`EP 2 072 051 A1, pp. 1-8,
`MED_DYM_00000362-369
`
`Australian Patent Application AU
`2003244799 B2 (6/13/03)
`MED_DYM_00002077-099 at 083-
`088
`
`Proposed Claim Amendment to
`Korean Patent Application No. 2004-
`7020819
`MED DYM 00002250-255 at 253-254
`
`PCT application PCT/GB02i04602
`
`{01056049;v1 }
`
`- 10 -
`
`
`
`
`
`Case 1:14-cv-01453-LPS Document 43 Filed 10/22/15 Page 14 of 16 PageID #: 217
`
`MED_DYM_00000262-274.
`
`MED_DYM_00000288-
`MED_DYM_00000306 (July 23,
`2009 Amendments and Response To
`Office Action Dated January 23,
`2009), see specifically
`MED_DYM_00000291-
`MED_DYM_00000296,
`MED_DYM_00000305.
`
`MED_DYM_00000455-
`MED_DYM_00000473 (Malhotra
`Declaration Submitted with July 23,
`2009 Amendment), see specifically
`MED_DYM_00000455-
`MED_DYM_00000459.
`
`MED_DYM_00000577-
`MED_DYM_00000596 (April 28,
`2010 Office Action), see specifically
`MED_DYM_00000578-596.
`
`MED_DYM_00000609-
`MED_DYM_00000629 (September
`24, 2010 Amendments and
`Response to Final Office Action
`Dated April 28, 2010),
`MED_DYM_00000609;
`MED_DYM_00000613-
`MED_DYM_00000617,
`MED_DYM_00000629.
`
`MED_DYM_00000654-
`
`(WO/2003/033000) (Published
`4/24/03) pp. 1-14
`MED_DYM_00003848-866 at 849-
`853
`
`WO/2003/066656, pp. 14-15, pp.18,
`MED_DYM_00004210-4225
`
`WO/2002/076933, pp. 21,
`MED_DYM_00004417-4438
`
`WO/2003/042229, pp. 9,
`MED_DYM_00004612-4621
`
`WO/2003/066033, pp. 18-19,
`MED_DYM_00004671-4690
`
`WO/2003/066036, pp. 15,
`MED_DYM_00004743-4758
`
`WO/2004/019955, pp. 3,
`MED_DYM_00004830-4833
`
`WO/2000/066522, pp. 96,
`MED_DYM_00006001-6008
`
`WO/2002/012266, pp. 17,
`MED_DYM_00006198-6215
`
`EP0416951, pp. 2-6,
`MED_DYM_00006263-6265
`
`WO/2001/078736, pp. 1, 4,
`MED_DYM_00006587-6591
`
`{01056049;v1 }
`
`- 11 -
`
`
`
`
`
`Case 1:14-cv-01453-LPS Document 43 Filed 10/22/15 Page 15 of 16 PageID #: 218
`
`MED_DYM_00000672 (Malhotra
`Declaration submitted with
`September 24, 2010 Amendment),
`see specifically
`MED_DYM_00000654-
`MED_DYM_00000658.
`
`MED_DYM_00000765-
`MED_DYM_00000780 (February
`16, 2011 Office Action), see
`specifically MED_DYM_00000773,
`MED_DYM_00000775-
`MED_DYM_00000777.
`
`MED_DYM_00000793-
`MED_DYM_00000820 (August 16,
`2011 Amendments and Response to
`Office Action Dated February 16,
`2011), see specifically
`MED_DYM_00000794,
`MED_DYM_00000798-
`MED_DYM_00000801,
`MED_DYM_00000820.
`
`MED_DYM_00002559-
`MED_DYM_00002570 (October 3,
`2012 Notice of Allowance), see
`specifically MED_DYM_00002563-
`MED_DYM_00002564,
`MED_DYM_00002567-
`MED_DYM_00002570.
`
`MED_DYM_00009006-
`MED_DYM_00009014 (January 30,
`
`WO/2000/048587, pp. 1-7,
`MED_DYM_00007157-7165
`
`WO/2001/078741, pp. 1-7,
`MED_DYM_00007775-7782
`
`WO/2001/078739, pp. 1-7,
`MED_DYM_00007791-
`7802WO/2001/078745, pp. 1,
`MED_DYM_00008003-8004
`
`WO/2002/100879, pp. 17,
`MED_DYM_00008683-8700
`
`WO/2000/049993, pp. 28,
`MED_DYM_00008861-8890
`
`U.S. Patent Application No.
`12/879,515; Original Application, pp.
`2, 8, 10-13; MED_DYM 00009277-
`9302
`
`U.S. Patent Application Publication
`No. U.S. 2004/0235807 A1 (published
`11/25/04) MED_DYM_00011174-191
`at 186.
`
`WO/2002/085296, pp.17,
`MED_DYM_00011403-1420
`
`WO/1992/014472, pp. 4,
`MED_DYM_00011722-1727
`
`WO/2003/033000, pp. 5,
`
`{01056049;v1 }
`
`- 12 -
`
`
`
`
`
`Case 1:14-cv-01453-LPS Document 43 Filed 10/22/15 Page 16 of 16 PageID #: 219
`
`2012 Supplemental Notice of
`Allowability).
`
`MED_DYM_00001454-
`MED_DYM_00001460 (Chopra
`Declaration Submitted with August
`16, 2011 Amendment), see
`specifically MED_DYM_00001455-
`MED_DYM_00001460.
`
`MED_DYM_00012077-2082
`
`WO/2004/019955, pp. 3, MED DYM
`00012948-2951
`
`Defendants reserve the right to rely
`upon any intrinsic evidence cited by
`Plaintiffs
`
`MED_DYM_00001334-
`MED_DYM_00001433 (Maus
`Declaration), see specifically
`MED_DYM_00001335-
`MED_DYM_00001340,
`MED_DYM_00001342-
`MED_DYM_00001343.
`
`MED_DYM_00001434-
`MED_DYM_00001453 (Rajan
`Declaration), see specifically
`MED_DYM_00001435-
`MED_DYM_00001437.
`
`Apotex_AZFL 0053488-
`Apotex_AZFL 0053496 (U.S. App.
`2006/0025391), see specifically
`Apotex_AZFL 0053495-
`Apotex_AZFL 0053496.
`
`Plaintiffs reserve the right to rely
`upon any intrinsic evidence cited by
`Defendants.
`
`{01056049;v1 }
`
`- 13 -